Menu Search
Equities

Madrigal Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
YDO1:STU

Madrigal Pharmaceuticals Inc

Actions
  • Price (EUR)402.60
  • Today's Change3.50 / 0.88%
  • Shares traded0.00
  • 1 Year change+25.73%
  • Beta-1.0098
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

  • Revenue in USD (TTM)740.64m
  • Net income in USD-289.13m
  • Incorporated2000
  • Employees528.00
  • Location
    Madrigal Pharmaceuticals Inc200 Barr Harbor Drive, Suite 400WEST CONSHOHOCKEN 19428United StatesUSA
  • Phone+1 (404) 380-9263
  • Fax+1 (302) 655-5049
  • Websitehttps://www.madrigalpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.